RIDGEBACK BIOTHERAPEUTICS
Ridgeback Biotherapeutics, founded by Wayne Holman and Wendy Holman is a privately held, majority woman-owned biotechnology company focused on orphan and infectious diseases. All funding for Ridgeback Biotherapeutics has originated from Wayne and Wendy Holman; two science-driven individuals who invest in technologies that they believe will make the world a better place. The team at Ridgeback is dedicated to working toward finding life-saving and life-changing solutions for patients and diseases that need champions.
RIDGEBACK BIOTHERAPEUTICS
Industry:
Biotechnology
Founded:
2016-01-01
Address:
Coconut Creek, Florida, United States
Country:
United States
Website Url:
http://www.ridgebackbio.com
Status:
Active
Contact:
305-602-5172
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.ridgebackbio.com Semrush global rank: 4.86 M Semrush visits lastest month: 1.83 K
- Host name: 172.67.151.148
- IP address: 172.67.151.148
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ridgeback Biotherapeutics"
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics develops potential medications to treat infectious diseases that have limited or no treatment options, like Ebola and COVID-19. Our Difference We commit …See details»
About Us - Ridgeback Biotherapeutics
Jun 8, 2021 · Founded in 2016, Ridgeback Biotherapeutics is a biotech company focused on developing transformational therapies to resolve or mitigate the …See details»
Ridgeback Biotherapeutics - Wikipedia
Ridgeback Biotherapeutics is a Miami -based biotechnology company, primarily known for its involvement in developing a successful COVID-19 medication. Ridgeback is privately owned …See details»
Leadership - Ridgeback Biotherapeutics
Jun 8, 2021 · At Ridgeback, we come to work every day to serve patients who need champions. Please read and learn about our leadership team – focused individuals dedicated to fighting …See details»
Ridgeback Biotherapeutics - Crunchbase Company …
Ridgeback Biotherapeutics is a biotechnology company focused on emerging infectious diseases and a a majority woman owned business. View contacts …See details»
Ridgeback Biotherapeutics - LinkedIn
Ridgeback Biotherapeutics is a biotechnology company focused on developing treatments and diagnostics for underserved patient populations primarily in pediatric orphan and emerging infectious...See details»
Ridgeback Biotherapeutics - Devex
Founded in 2016, Ridgeback Biotherapeutics is a biotech company focused on developing transformational therapies to resolve or mitigate the effects of emerging infectious diseases.See details»
CNBC Transcript: Ridgeback Biotherapeutics Co-Founders Dr.
Oct 1, 2021 · Following is the unofficial transcript of a CNBC interview with Ridgeback Biotherapeutics Co-Founders Dr. Wayne Holman and Wendy Holman on CNBC’s “Squawk on …See details»
What can we help you find? - Merck
Mar 6, 2021 · Headquartered in Miami, Florida, Ridgeback Biotherapeutics LP is a biotechnology company focused on emerging infectious diseases. Ridgeback markets EbangaTM for the …See details»
Lagevrio (molnupiravir) - Ridgeback Biotherapeutics
May 14, 2024 · Lagevrio (molnupiravir) is a direct-acting oral, broad-spectrum antiviral agent in clinical development as a treatment for COVID-19. Ridgeback has completed Phase 1 and Phase 2 studies.See details»
Merck and Ridgeback Bio Announce Closing of Collaboration and …
Jul 1, 2020 · Under the agreement, announced on May 26, 2020, Merck, through a subsidiary, has acquired exclusive worldwide rights to develop EIDD-2801 and related molecules in …See details»
Wendy Holman - CEO & Co-founder - Crunchbase
Wendy Holman is the CEO of Ridgeback Biotherapeutics, the company she co-founded with her husband Dr. Wayne Holman. Wendy Holman was motivated by her commitment to world …See details»
Ansuvimab: First Approval - PMC - PubMed Central (PMC)
Ansuvimab (ansuvimab-zykl; EBANGAâ„¢) is a human monoclonal antibody developed by Ridgeback Biotherapeutics, which binds to the glycoprotein on Zaire ebolavirus (Ebola virus) …See details»
Ridgeback Biotherapeutics - Overview, News & Similar ... - ZoomInfo
Oct 1, 2021 · Ridgeback Biotherapeutics contact info: Phone number: (786) 687-2495 Website: www.ridgebackbio.com What does Ridgeback Biotherapeutics do? Ridgeback Biotherapeutics …See details»
Pipeline - Ridgeback Biotherapeutics
In a biotechnology universe of over 20,000 companies, we are one of the 150 companies who have an FDA approved biologic that serves patients. Our patient-guided mission allows us to …See details»
Ridgeback Biotherapeutics - Company info. interviews, news
Ridgeback Biotherapeutics is a biotechnology company focused on developing treatments and diagnostics for underserved patient populations primarily in pediatric orphan and emerging …See details»
Ansuvimab: First Approval | Drugs - Springer
Mar 22, 2021 · Ansuvimab (ansuvimab-zykl; EBANGAâ„¢) is a human monoclonal antibody developed by Ridgeback Biotherapeutics, which binds to the glycoprotein on Zaire ebolavirus …See details»
Press Coverage for Ridgeback Biotherapeutics
Feb 8, 2024 · Prevention is better than healing. Clinical and economic implications of oral antiviral agents in COVID-19: a prospective study. Excellence Awards 2022 – Winners Announced! …See details»
Ansuvimab: First Approval. - Abstract - Europe PMC
Mar 22, 2021 · Ansuvimab (ansuvimab-zykl; EBANGAâ„¢) is a human monoclonal antibody developed by Ridgeback Biotherapeutics, which binds to the glycoprotein on Zaire ebolavirus …See details»
Career Opportunities - Ridgeback Biotherapeutics
Ridgeback Biotherapeutics commits resources and expertise for undefined and poorly understood diseases early in the pharmaceutical development cycle, at a time generally when few …See details»